"28-day mortality in high-risk with severe sepsis receiving eritoran with or without drotrecogin alfa: Analysis of data from a phase II trial" by Mark Tidswell, MD

Article

28-day mortality in high-risk with severe sepsis receiving eritoran with or without drotrecogin alfa: Analysis of data from a phase II trial

All Scholarly Works

Mark Tidswell, MD, Baystate Health

Document Type

Presentations, Research

Publication Date

1-1-2010

Citation Information

Kinasewitz g, Tidswell M. 28-day mortality in high-risk with severe sepsis receiving eritoran with or without drotrecogin alfa: Analysis of data from a phase II trial. Society of Critical Care Medicine Critical Care Congress. San Diego, CA. 2010.